Supplementary Figure 3 from Targeting FoxM1 Effectively Retards p53-Null Lymphoma and Sarcoma
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 216 KB, A, FoxM1 IHC staining of 5 micron allografted sarcoma tissue of control group. B, tamoxifen treated group. C, thymic lymphoma control group. D, thymic lymphoma tamoxifen group. E-F and I-J, Representative TUNEL and DAPI staining of tumor sections from the subcutaneously inoculated CreERT2 Foxm1 fl/fl and p53 -/- sarcoma after tamoxifen or control treatment are shown. G-H and K-L, Representative TUNEL and DAPI staining of tumor sections from the subcutaneously inoculated CreERT2 Foxm1 fl/fl and p53 -/- thymic lymphoma after tamoxifen or control treatment are shown. M, quantification of number of positive cleaved-caspase 3 (Asp175) cells per field of thymic lymphoma is shown. N, quantification of number of positive cleaved-PARP (Asp214) cells per field of thymic lymphoma is shown.
Authors: Zebin Wang, Yu Zheng, Hyun Jung Park, Jing Li, Janai R. Carr, Yi-ju Chen, Megan M. Kiefer, Dragana Kopanja, Srilata Bagchi, Angela L. Tyner, Pradip Raychaudhuri
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362478280